Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Shengmai Liquid

Phase 3Small molecule

BBeijing University of Chinese Medicine

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Fatigue

NCT06980636

Clinical

Trials by Indication[1]

Hypotension1 trial

The Clinical Study of Improving the Thirst and Hypotension of Hemodialysis Patients

Unknown status·—·Phase 2/3·NCT02583802·150 enrolled

Fatigue1 trial

A Trial of Shengmai Liquid for Long COVID Fatigue.

Recruiting·—·Phase 4·NCT06980636·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Shengmai Liquid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Shengmai Liquid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Shengmai Liquid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing University of Chinese Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBeijing University of Chinese Medicine

Related News